Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

1.9K

HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s

Ling Li1, Wenhua Tang, Xiaoqing Wu

  • 1Authors' Affiliations: Departments of Radiation Oncology and Surgery, University of Michigan Medical Center; Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan; Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an; Department of Hematology/Oncology, Hainan University Medical School, Haikou, Hainan, China; Departments of Molecular Biosciences and Radiation Oncology, University of Kansas, Lawrence, Kansas; Department of Pediatrics, College of Medicine; and Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 18, 2013
PubMed
Abstract

Insights

HAb18G/CD147 promotes pancreatic cancer by activating STAT3 signaling. Targeting HAb18G/CD147 may offer a new therapeutic strategy for pancreatic cancer patients with poor prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Signal transducer and activator of transcription 3 (STAT3) is crucial in pancreatic cancer initiation and progression.
  • Therapeutic targeting of STAT3 has shown limited clinical success.
  • HAb18G/CD147 has been identified as a potential target for cancer treatment.

Purpose of the Study:

  • To investigate the role of HAb18G/CD147 in STAT3-mediated pancreatic tumorigenesis.
  • To explore the molecular mechanisms linking HAb18G/CD147 and STAT3 in pancreatic cancer.
  • To evaluate HAb18G/CD147 as a potential therapeutic target and prognostic marker.

Main Methods:

  • Assessed HAb18G/CD147, pSTAT3, and CD44s expression in pancreatic cancer tissues.
  • Utilized in vitro and in vivo models with loss/gain-of-function strategies to study tumorigenic function.
  • Employed reporter assays, immunoblotting, immunofluorescence, and immunoprecipitation to elucidate signaling pathways.

Main Results:

  • High HAb18G/CD147 expression correlated with enhanced cellular growth, tumorigenicity, and poor tumor differentiation.
  • Cyclophilin A (CyPA) binding to CD147 activated STAT3 phosphorylation and downstream genes (cyclin D1, survivin).
  • HAb18G/CD147 colocalized with CD44s in lipid rafts; targeting STAT3, survivin, or CD44s inhibited HAb18G/CD147-induced growth.
  • Coexpression of HAb18G/CD147, CD44s, and STAT3 predicted poor patient survival.

Conclusions:

  • HAb18G/CD147 acts as an upstream activator of STAT3 in pancreatic cancer, interacting with CD44s.
  • HAb18G/CD147 plays a critical role in pancreatic cancer development and progression.
  • HAb18G/CD147 represents a promising therapeutic target and surrogate marker for STAT3-targeted therapies in aggressive pancreatic cancer.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

13.3K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

11.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K